THE breakthrough in the treatment of prostate cancer which has been reported by scientists at Ulster University will hopefully prove to be of major importance.
Researchers believe that combining an existing hormone therapy with a new drug known as OCT1002 will significantly improve the prospects of sufferers.
The potentially fatal prostate condition is the most common form of cancer for men in Northern Ireland, with around 1,000 cases detected annually.
While a high percentage already result in a positive outcome, there will be enormous relief if even more of those who are diagnosed can be told that they are likely to make a full recovery.
